firsocostat
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 21, 2018 (NCT03449446)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Acetyl-CoA carboxylase 2INHIBITOR
ACACB inhibitor
- Acetyl-CoA carboxylase 1INHIBITOR
ACACA inhibitor
- Acetyl-CoA carboxylaseNEGATIVE ALLOSTERIC MODULATOR
Acetyl-CoA carboxylase negative allosteric modulator
Allosteric inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1- Mol. weight
- 569.64 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3407547 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04971785 | Phase 2 | Aug 9, 2021 | Gilead Sciences, Novo Nordisk |
| NCT03987074 | Phase 2 | Aug 31, 2019 | Gilead Sciences, Novo Nordisk |
| NCT03449446 | Phase 2 | Mar 21, 2018 | Gilead Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 3 | 3 | 1 | 2018 |
| Novo Nordisk | For profit | 2 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1